Andrzej J Jakubowiak, MD, PhD¹, Sebastien Anguille^2*, Lionel Karlin^3*, Ajai Chari, MD^4*, Carolina Schinke, MD⁵, Leo Rasche, MD^6*, Jesus San-Miguel, MD, PhD⁷, Michela Campagna, PhD^8*, Brandi W Hilder, PhD⁹, Tara J Masterson, MS^9*, Xiang Qin^9*, Thomas Renaud, MD¹⁰, Jaszianne Tolbert, MD⁹, Deeksha Vishwamitra, PhD⁹, Sheri Skerget^9* and Philippe Moreau, MD, PhD^11*

¹University of Chicago, Chicago, IL
²Vaccine and Infectious Disease Institute, University of Antwerp, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
³Centre Hospitalier Lyon Sud, Pierre-Bénite, France
⁴at the time that the work was performed, Mount Sinai School of Medicine, New York, NY
⁵Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
⁶University Hospital of Würzburg, Würzburg, Germany
⁷University of Navarra, Pamplona, Spain
⁸Janssen Research & Development, Madrid, Spain
⁹Janssen Research & Development, Spring House, PA
¹⁰Janssen Research & Development, Raritan, NJ
¹¹Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France

Ravi Vij, MD, MBA¹, Shaji Kunnathu Kumar, MD², Anita D'Souza, MD, MS³, John T Mckay, MD^4*, Peter M. Voorhees, MD⁵, Alfred Chung, MD⁶, Sascha Alexander Tuchman, MD, MHS⁷, Neha Korde, MD⁸, Katja Weisel, MD⁹, Raphael Teipel, MD^10*, Orlando Bueno, MD, PhD¹¹, Zhongling Feng, MD, PhD^12*, Tanya S Rosenberg, MD^11*, Rajvineeth Kumar Pothacamury, MD^13*, Akshanth R Polepally, PhD^11*, Shane Lee, MS^14*, Ziyi Jin, MS^13*, Jeremy A Ross, PhD^11*, Aarif Ahsan^15*, Chetasi Talati, MD¹⁶ and Cesar Rodriguez, MD^17*

¹Division of Oncology, Washington University School of Medicine, Saint Louis, MO
²Division of Hematology, Mayo Clinic, Rochester, MN
³The Medical College of Wisconsin Inc, Milwaukee, WI
⁴Wake Forest School of Medicine, Winston-Salem, NC
⁵Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
⁶Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
⁷Division of Hematology, University of North Carolina School of Medicine, Chapel Hill, NC
⁸Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁹University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
¹⁰Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany
¹¹AbbVie Inc., North Chicago, IL
¹²AbbVie Inc., Cambridge, MA
¹³AbbVie, North Chicago
¹⁴AbbVie Inc., North Chicago
¹⁵AbbVie, Inc., North Chicago, IL
¹⁶AbbVie, Inc., Collierville, TN
¹⁷Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York

Binod Dhakal, MD, MS^1*, Meera Mohan, MD², Ravi Narra, MD^2*, Katie Palen^3*, Aniko Szabo, PhD^4*, Tyce Kearl, MD^5*, Gayathri Ravi, MD⁶, Susan Bal, MD^6*, Bryon D. Johnson, PhD^7*, Marcelo Pasquini, MD, MS⁸, Anita D'Souza, MD, MS⁴, Parameswaran N. Hari, MD, MBBS⁷ and Luciano Costa, MD, PhD⁶

¹BMT and Cellular Therapy, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
²BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
³Medical College of Wisconsin, Wauwatosa, WI
⁴Medical College of Wisconsin, Milwaukee, WI
⁵Division of Hematology/Oncology, Medical College of Wisconsin, MIlwaukee, WI
⁶University of Alabama at Birmingham, Birmingham, AL
⁷Department of Medicine, Medical College of Wisconsin, Milwaukee
⁸Froedtert & The Medical College Cancer Ctr., Milwaukee, WI

Manisha Bhutani, MD¹, Myra Robinson, PhD^2*, Shebli Atrash, MD^1*, Barry Paul, MD, MS¹, Mauricio Pineda-Roman, MD^1*, David Foureau, PhD³, Cindy Varga, MD^1*, Reed Friend, MD¹, Xhevahire Begic^4*, Sarah Norek^4*, Tiffany Drennan^5*, Michelle B Anderson^6*, James Symanowski, PhD^2*, Peter M. Voorhees, MD⁷ and Saad Z Usmani, MD⁸

¹Department of Hematologic Oncology & Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
²Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC
³Immune Monitoring Core Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC
⁴Sponsored Research Coordinating Center, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁵Clinical Trials Unit, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁶Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
⁸Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Frida Bugge Askeland, MD^1,2*, Einar Haukås, MD^3*, Tobias S. Slørdahl, MD, PhD^4*, Anja Klostergaard, MD^5*, Tatjana Alexandersen^6*, Diana Schjøll^6*, Anna Lysen, PhD^1,2*, Emil Hermansen, MD, PhD^7* and Fredrik Schjesvold, MD, PhD^2,8

¹Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
²KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
³Department of Cancer and Blood Diseases, Stavanger University Hospital, Stavanger, Norway
⁴Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
⁵Department of Hematology, Aarhus University Hospital, Aarhus N, Denmark
⁶Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
⁷Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
⁸Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway

Omar Nadeem, MD¹, Sophie Magidson, BS^1*, Robert A. Redd, MS^2*, Jacob Laubach³, Clifton C. Mo, MD¹, Elizabeth K. O'Donnell, MD¹, Adam S. Sperling, MD, PhD¹, Monique A Hartley-Brown, MD⁴, Shonali Midha, MD, BS^1*, Marjorie Marto^1*, Christine Davie^1*, Caroline Ricciardi^1*, Dechen Choden^1*, Ashlee Strutevant^1*, Jillian Alberti^1*, Lorenzo Trippa^1*, Nikhil C Munshi, MD^1*, Kenneth C. Anderson, MD⁵, Paul G. Richardson, MD¹ and Irene M. Ghobrial, MD¹

¹Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Dana-Farber/Partners CancerCare, Harvard Medical School, Boston, MA
⁴DFCI, Boston, MA
⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Barry Paul, MD, MS¹, Jirí Minarík^2*, Francesca Cottini, MD³, Cristina Gasparetto^4*, Jack Khouri, MD⁵, Mitul Gandhi, MD⁶, Jens Hillengass, MD, PhD⁷, Moshe Levy^8*, Michaela Liedtke, MD⁹, Sudhir Manda¹⁰, Irwindeep Sandhu¹¹, Douglas Sborov, MD, MS¹², Ivan Spicka^13*, Saad Z Usmani, MD¹⁴, Lin Gu^15*, Michelle Robeson^15*, Michael Murphy^15*, Camille Renard^15*, Christine Chen, MHPE, MD, FRCPC¹⁶ and Luděk Pour, MD^17*

¹Levine Cancer Institute, Charlotte, NC
²Fakultní Nemocnice Olomouc, Olomouc, CZE
³The Ohio State University, Columbus, OH
⁴Duke Cancer Institute, Durham, NC
⁵Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁶US Oncology Site - Virginia Cancer Specialists, Fairfax, VA
⁷Roswell Park, Buffalo, NY
⁸Baylor University Medical Center, Dallas, TX
⁹Stanford Cancer Center, Palo Alto, CA
¹⁰Arizona Oncology Associates, Tucson, AZ
¹¹Cross Cancer Institute, Edmonton, AB, Canada
¹²Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
¹³Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic
¹⁴Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Gilead Sciences, Inc., Foster City, CA
¹⁶Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada
¹⁷University Hospital Brno, Brno, CZE

Ruben Niesvizky, MD¹, Bertrand Arnulf, MD, PhD², Mohamad Mohty, MD, PhD³, Ajay K. Nooka, MD, MPH⁴, Salomon Manier, MD, PhD⁵, Michael Tomasson, MD^6*, Nizar J Bahlis, MD⁷, Donald Irby, PhD^8*, Jennifer Hibma, PharmD^9*, Andrea Viqueira, MD^10*, Eric Leip^11* and Alexander Lesokhin, MD^12,13

¹Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
²Hôpital Saint-Louis, APHP, Université Paris cite, Paris, France
³Saint-Antoine Hospital, Sorbonne University, Paris, France
⁴Winship Cancer Institute, Emory University, Atlanta, GA
⁵Lille University Hospital and INSERM UMR-S1277, Lille, France
⁶University of Iowa, Iowa City, IA
⁷Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁸Pfizer, Franklin, OH
⁹Pfizer, San Diego, CA
¹⁰Pfizer SLU, 28108, Madrid, ESP
¹¹Pfizer, Cambridge, MA
¹²Weill Cornell Medicine, New York, NY
¹³Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Michael Tomasson, MD^1*, Shinsuke Iida², Ruben Niesvizky, MD³, Mohamad Mohty, MD, PhD⁴, Nizar J Bahlis, MD⁵, Joaquin Martinez-Lopez, MD, PhD^6*, Guenther Koehne, MD, PhD⁷, Paula Rodriguez Otero, MD, PhD^8*, H. Miles Prince, MD⁹, Andrea Viqueira, MD^10*, Eric Leip^11*, Umberto Conte, PharmD^12*, Sharon T Sullivan^11* and Alexander Lesokhin, MD^13,14

¹University of Iowa, Iowa City, IA
²Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
³Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
⁴Saint-Antoine Hospital, Sorbonne University, Paris, France
⁵Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁶Hospital Universitario 12 de Octubre, CIBER-ONC CB16/12/00369, CNIO, Madrid, Spain
⁷Baptist Health South Florida, Miami Cancer Institute, Miami, FL
⁸Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain
⁹Epworth Freemasons, Melbourne VIC, Australia
¹⁰Pfizer SLU, 28108, Madrid, ESP
¹¹Pfizer, Cambridge, MA
¹²Pfizer, New York, NY
¹³Weill Cornell Medicine, New York, NY
¹⁴Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Noa Biran^1*, Binod Dhakal, MBBS², Ruben Niesvizky, MD³, Suzanne Lentzsch, MD, PhD⁴, John T. McKay^5*, David H. Vesole, MD, PhD^6,7, Ajay K. Nooka, MD, MPH⁸, Barry Paul, MD, MS⁹, Parameswaran N. Hari, MD, MBBS¹⁰, Lisette Stork-Sloots^11*, Silvia D'Ambrosi^12*, Rowan Kuiper^12*, Martin van Vliet^12*, David S. Siegel, MD, PhD¹, Saad Z Usmani, MD¹³ and Frits van Rhee, MD, PhD¹⁴

¹Hackensack University Medical Center, Hackensack, NJ
²BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
³Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
⁴Division of Hematology & Oncology, Columbia University Medical Center, New York, NY
⁵Wake Forest University School of Medicine, Winston-Salem, NC
⁶Lombardi Comprehensive Cancer Center, Medstar Georgetown Medical Center, Washington, DC, DC
⁷Multiple Myeloma Division, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
⁸Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
⁹Department of Hematologic Oncology & Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
¹⁰Department of Medicine, Medical College of Wisconsin, Milwaukee
¹¹Medex15, Amsterdam, Netherlands
¹²SkylineDx, Rotterdam, Netherlands
¹³Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR

Joshua Richter, MD¹, Jeffrey A. Zonder, MD², Nitya Nathwani, MD³, Giada Bianchi, MD⁴, Craig C. Hofmeister, MD⁵, Ravi Vij, MD, MBA⁶, Matthew Pianko⁷, Gurbakhash Kaur, MD, MA⁸, Malin Hultcrantz, MD, PhD⁹, Katie Wozniak^10*, Mercedes Martillo^10*, Hearn Jay Cho, MD¹¹ and Shaji Kunnathu Kumar, MD¹²

¹Icahn School of Medicine at Mount Sinai, New York, NY
²Karmanos Cancer Institute, Detroit, MI
³Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Winship Cancer Institute of Emory University, Atlanta
⁶Siteman Cancer Center, Washington University, Saint Louis, MO
⁷Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI
⁸Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
⁹Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰The MMRF, Norwalk, CT
¹¹Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY
¹²Division of Hematology, Mayo Clinic, Rochester, MN

Weijun Fu^1*, Soo-Mee Bang, MD, PhD², Honghui Huang, PhD, MD^3*, Kihyun Kim^4*, Wei Li^5*, Gang An^6*, Je-Jung Lee^7*, Zhen Cai^8*, Jie Jin⁹, Yafei Wang^10*, Chor Sang Chim, MD, PhD, BMBS^11*, Robin Carson, MD, BA¹², Rui Liu^13*, Lingling Wang^14*, Man Zhao^15*, XI Chen, PhD^16*, Canchan Cui^17*, Jian Hou^3* and Jianxiang Wang, MD⁶

¹Shanghai Changzheng Hospital, Shanghai, China
²Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, KOR
³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁵The First Hospital of Jilin University, Changchun, China
⁶Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁷Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun, Korea, Republic of (South)
⁸Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁹The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
¹⁰Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
¹¹Hong Kong Sanatorium & Hospital, Hong Kong, China
¹²Janssen Research & Development, LLC, Spring House, PA
¹³Johnson & Johnson China Ltd, Beijing, China
¹⁴Janssen China Research and Development, Beijing, China
¹⁵IQVIA, Shanghai, China
¹⁶Xian Janssen Pharmaceutical Ltd.; Xian Janssen Pharmaceutical Ltd., Beijing; Shanghai, China
¹⁷Xian Janssen Pharmaceutical Ltd., Beijing, China

Adam D. Cohen, MD¹, Wei-Ting Hwang, PhD^2*, Sandra Susanibar-Adaniya, MD¹, Dan T. Vogl, MD, MSCE¹, Alfred L. Garfall, MD, MTR¹, Adam Waxman, MD^1*, Danielle Zubka, RN^1*, Chau Nguyen, RN^1*, Cynthia Diaczynsky^1*, Marco Ruella, MD³, Michael C. Milone, MD, PhD^4* and Edward A. Stadtmauer, MD¹

¹Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
²Department of Biostatistics, Epidemiology, and Informatics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
³Lymphoma Program, University of Pennsylvania, Philadelphia, PA
⁴Center for Cellular Immunotherapies, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

Karthik Ramasamy, MD^1,2,3, David Allan Cairns, PhD^4*, Kara-Louise Royle^5*, Robert Cicero, MSc^5*, Catherine Olivier^5*, Lorna Barnard^5*, Sharon Jackson^6*, Doina Levinte^5*, Gordon Cook, PhD^5,7*, Alan Chant^8*, David Meads, PhD^9*, Bryony Dawkins^9*, Michael A. Chapman, MD PhD^10,11, Guy Pratt, MD^12*, Rakesh Popat^13,14*, Graham Jackson^15,16*, Ceri Bygrave, MD, FRCPath, MPhil^17*, Andrew Chantry^18*, Martin F. Kaiser, MD, FRCP, FRCPath¹⁹, Jonathan Sive, MD^20*, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD^5,7, Dean Smith^21*, Matthew W. Jenner^22*, Mark Drayson^23*, Roger Owen, MD, MRCP, FRCPath^24*, Ruth M de Tute, MSc, PhD, FRCPath^25*, Dipal Mehta, MBBS MRCP^26* and Kwee Yong²⁷

¹NDORMS, Oxford Translational Myeloma Centre, Oxford, United Kingdom
²Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
³University of Oxford, Oxford, United Kingdom
⁴Leeds Institute of Clinical Trials Research, Cancer Research UK Clinical Trials Unit, Leeds, ENG, United Kingdom
⁵Leeds Institute of Clinical Trials Research, Cancer Research UK Clinical Trials Unit, Leeds, United Kingdom
⁶Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
⁷Leeds Myeloma Research Group and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
⁸Patient and Public Contributor, NA, United Kingdom
⁹University of Leeds, Academic Unit of Health Economics, Leeds, United Kingdom
¹⁰Department of Haematology, University of Cambridge, Cambridge, United Kingdom
¹¹MRC Toxicology Unit, University of Cambridge, Cambridge, United Kingdom
¹²Birmingham Heartlands Hospital, Birmingham, GBR
¹³NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹⁴University College London, London, United Kingdom
¹⁵University of Newcastle, Department of Haematology, Newcastle, United Kingdom
¹⁶Newcastle University, Newcastle, United Kingdom
¹⁷Haematology, University Hospital Wales, Cardiff, United Kingdom
¹⁸University of Sheffield, Department of Oncology and Metabolism The Medical School Beech Hill Road, Sheffield, GBR
¹⁹The Institute of Cancer Research, London, ENG, United Kingdom
²⁰Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
²¹Department of Clinical Haematology, Nottingham University Hospitals, Nottinghamshire, United Kingdom
²²University Hospital Southampton, Southampton, United Kingdom
²³University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
²⁴Leeds Teaching Hospitals NHS Trust, Haematological Malignancies Diagnostics Service, Leeds, United Kingdom
²⁵HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
²⁶Research Department of Haematology, University College London Cancer Institute, Buckhurst Hill, ENG, United Kingdom
²⁷Department of Haematology, University College London, London, United Kingdom

Jesus G. Berdeja, MD¹, David Dingli, MD², Sagar Lonial, MD^3*, Andrew J. Yee, MD⁴, Alfred Chung, MD⁵, Cristina Gasparetto, MD^6*, P. Leif Bergsagel, MD⁷, Vivek Roy, MD⁸, Al-Ola Abdallah, MD^9,10, Sharmilan Thanendrarajan, MD^11*, Aimaz Afrough, MD¹², Laura Rosiñol, MD, PhD^13*, Suzanne Trudel, MD, FRCPC¹⁴, Paula Rodriguez Otero, MD, PhD^15*, Cyrille Touzeau, MD, PhD^16*, Pierre Bories, MD, PhD^17*, Soo Bang, MHSA^18*, Terry Connolly, PhD^18*, Michelle Kim^18*, Chad A. Lewis, PhD^18*, Bao-Van Tran Linberg^18*, M. Travis Quigley^18*, Ola Landgren, MD¹⁹, Saad Z Usmani, MD²⁰, Maria-Victoria Mateos²¹ and David S. Siegel, MD, PhD²²

¹Sarah Cannon Research Institute, Nashville, TN
²Mayo Clinic, Rochester, MN
³Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
⁴Massachusetts General Hospital Cancer Center, Boston, MA
⁵Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
⁶Duke Cancer Institute, Duke University Medical Center, Durham, NC
⁷Mayo Clinic, Phoenix, AZ
⁸Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL
⁹University of Kansas Medical Center, Kansas City, KS
¹⁰US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
¹¹Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
¹²Hematologic Malignancies and Cellular Therapy, University of Texas Southwestern Medical Center, Dallas, TX
¹³Hematopoietic Cell Transplantation Unit,, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
¹⁴Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
¹⁵Centro de Investigacion Biomedica en Red de Cancer (CIBERONC)., Madrid, Spain
¹⁶University Hospital Nantes, Nantes, France
¹⁷Toulouse University Institute of Cancer, Toulouse, FRA
¹⁸K36 Therapeutics, Cambridge, MA
¹⁹Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
²⁰Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²¹University Hospital of Salamanca/IBSAL, Salamanca, Spain
²²Multiple Myeloma Division, Hackensack Univ. Med. Ctr., Hackensack, NJ

Ola Landgren, MD¹, Francesco Maura, MD² and Dickran Kazandjian, MD³

¹Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
²Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, PALMETTO BAY, FL
³Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

Paula Rodriguez Otero, MD, PhD^1*, Maria-Victoria Mateos², Oluwaseun Aina^3*, Arijit Sinha^4*, Andrew J Steele^3*, Anasuya Hazra^3*, Karen Rodriguez Lorenc³, Glenn S. Kroog^3*, Shawn M Sarkaria^3* and Jesus San Miguel^5*

¹Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada. Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain
²Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
⁴Regeneron UK Ltd., Uxbridge, United Kingdom
⁵Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

Beatrice Razzo, MD¹, Connor Grady, MPH^2*, Sandra Susanibar-Adaniya, MD¹, Adam Waxman, MD^1*, Dan T. Vogl, MD, MSCE¹, Adam D. Cohen, MD¹, Edward A. Stadtmauer, MD¹, Wei-Ting Hwang, PhD^3* and Alfred L. Garfall, MD, MTR¹

¹Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
²Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
³Department of Biostatistics, Epidemiology, and Informatics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Ana Maria Avila Rodriguez, MD¹, Danny Hadidi, MD^1*, Craig C. Hofmeister, MD², John Quigley, MD¹, Maria Zappia, PhD^3*, Maxim Frolov, PhD^3*, Elizaveta Benevolenskaya, PhD^3*, Matias Eugenio Sanchez, MD¹, Shrihari Kadkol, PhD^4*, Douglas Sborov, MD, MS⁵, Damiano Rondelli, MD^1*, Chukwuemeka Uzoka, MD¹ and Karen Sweiss, PharmD⁶

¹Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL
²Department of Hematology & Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
³Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL
⁴University of Illinois At Chicago, Chicago, IL
⁵University of Utah School of Medicine, Salt Lake City, UT
⁶Department of Pharmacy Practice, University of Illinois at Chicago, Hinsdale, IL

Hanlon Sia^1*, Vinu Menon^2*, Andrew Garton, PhD^3*, Eileen Wolff^3*, Tejas Shah^3*, Colleen Charpentier^4*, Dominique Duchesne^3*, Maria Pihlgren^5*, Jeppe Seestern Koch-Olsen^4*, Adam Drake^6*, Mario Perro, PhD^6*, Eugene Zhukovsky⁷, Lida Pacaud, MD^2* and Cyril Konto, MD²

¹Pindara Private Hospital, Benowa, QLD, AUS
²Ichnos Sciences, New York, NY
³Ichnos Sciences Inc., New York
⁴Ichnos Sciences, New York
⁵Ichnos Sciences SA, Epalinges, Switzerland
⁶Ichnos Sciences Biotherapeutics SA, Epalinges, Switzerland
⁷Ichnos Sciences Biotherapeutics SA, Lausanne, Switzerland